The February 2026 edition (No. 334) of Pharmaceutiques features an in‑depth article on DNDi’s model for developing new treatments for neglected diseases through public–private partnerships. The piece highlights the recent submission by DNDi and Sanofi’s Foundation S to the EMA for scientific review of a novel molecule targeting sleeping sickness, as well as several other ongoing collaborations, including some focused on dengue.
